Northwire Canada EditionSaturday, October 17, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
Regulatory

Mindbio Therapeutics begins trading on OTCQB

By The Northwire Desk — AI Analysis Jan 21, 2026 · 19:46 MBIO · 1.05 Mindbio Therapeutics Corp
MBIO · Price

Executive Summary

  • Mindbio Therapeutics Corp. has listed its common shares for trading on the OTCQB market, expanding its investor base to include U.S. investors.
  • The listing coincides with the launch of an extended roadshow for its voice and AI-powered drug and alcohol intoxication technology in the United States.
  • The company is developing an enterprise version of its technology and a new platform for health prediction using human voice analytics, with plans to announce progress on new products and commercial applications shortly.

Key Details

  • Listing Venue: OTCQB Market.
  • Technology: AI model using over 50 million data points to predict alcohol intoxication via human voice; estimates actual blood alcohol concentration levels.
  • Product Launch: Successful 2025 launch of the "Booze AI app."
  • Target Markets: Workplace environments, call centres, mental health, and law enforcement.
  • Strategic Focus: Development of an enterprise version and new platform-level technology for health prediction using the human voice.
  • CEO Commentary: Justin Hanka stated the listing allows the company to reach U.S. investors interested in AI and predictive health technologies.

Notable Quotes

  • "We are pleased to now reach U.S. investors and a much larger investor audience, particularly those U.S. investors interested in AI and predictive health technologies, via our OTCQB listing." — Justin Hanka, Chief Executive Officer
Read the original news release →

More from Mindbio Therapeutics Corp

Jun 09, 2026 · 07:00

From failed psychedelics to unproven AI kiosks: MindBio bets its survival on voice analytics, but cash burn and dilution loom.

Production / Operations Jun 04, 2026 · 11:12

MindBio’s Voice AI Pivot Buys Time, But Cash Runway and Dilution Risk Keep the Stock in the Red Zone

Other May 15, 2026 · 08:30

MindBio's AI Pivot Masks Failed Drug Trial and Dilution Risk

Other May 14, 2026 · 08:30

MindBio Pivots from Failed Psychedelic Trial to AI Voice Detection Amidst Dilution Concerns

Other May 13, 2026 · 08:30

MindBio Pivots to AI Voice Tech After Clinical Setback; Dilution Risks Loom

Other May 11, 2026 · 08:45

MindBio Pivots from Clinical Failure to AI Voice Analytics, But Dilution Risks Loom

Other